Navigating CLL Management: Treatment Landscape, Patient Care, and Quality of Life - Episode 6

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

September 13, 2024

The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.

EP. 1: Connections: Understanding CLL: Symptoms, Diagnosis, and What Patients Need to Know
EP. 2: Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights
EP. 3: Watchful Waiting in CLL: When Waiting Is Treating
EP. 4: LL Treatment Roadmap: Navigating First-Line Options With Your Doctor
EP. 5: CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
Now Viewing
EP. 6: Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
EP. 7: Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors
EP. 8: The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration

Video content above is prompted by the following:

  • Can you explain what fixed-duration treatments are and how they differ from continuous therapy in CLL?
  • Please briefly highlight venetoclax-based regimens, which are approved for 12 cycles in the frontline setting with obinutuzumab and 24 cycles in the relapsed/refractory setting with rituximab.?

Related Content:

Navigating CLL Management: Treatment Landscape, Patient Care, and Quality of LifeVideo SeriesCLLCURE Expert Connections
Polycythemia Vera: Overview
Imbruvica-Venetoclax Shows Promise in Managing CLL
With CLL, I Try to Make the Best of Everything